2 replies to this topic

[stefan_001]

https://academic.oup.../ddy278/5057892

 

We showed here that NAD+ salvage pathway was altered in the heart of mouse and human carrying LMNA mutation, leading to an alteration of one of NAD+ co-substrate enzymes, PARP-1. Oral administration of nicotinamide riboside, a natural NAD+ precursor and a pyridine-nucleoside form of vitamin B3, leads to a marked improvement of the NAD+ cellular content, an increase of PARylation of cardiac proteins, and an improvement of left ventricular structure and function in a model of LMNA cardiomyopathy.

[albedo]

Interesting, thank you. Just in case you overlooked, a recent interview with Dr. Brenner was posted here in which I recollect he did mention cardiovascular benefits too potentially related to the research your just posted.

[able]

I’m surprised this study didn’t get any discussion here, as it clearly  shows NR is not the same as NAM.

 

The mice had gene mutation resulting in low NAMPT levels, poor salvage and low NAD+ levels.  

 

400 Mg/kg of NR rescued NAD+ levels and increased survival.  500 Mg/kg of NAM did not raise NAD+ levels in the heart OR liver.

 

Since they could not use NAM in the heart to restore NAD+ levels, doesn’t that mean SOME NR is making it through the liver to the heart?

 

 

The Liu study showed that  with a smaller dose of 50 Mg/Kg bodyweight, all NR and NMN get metabolized to NAM in GI tract and liver.

 

So, is the huge dose possibly "overwhelming" the liver, and some NR makes it to the bloodstream and on to the heart?